Opus Genetics, Inc. Total Liabilities and Equity
Opus Genetics, Inc. (IRD) had Total Liabilities and Equity of $92.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $92.97M.
- 2026-03-31: Liabilities and Equity $66.79M.
- 2025-12-31: Liabilities and Equity $50.24M.
- 2025-09-30: Liabilities and Equity $36.12M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $92.97M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $66.79M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $50.24M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $36.12M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $38.66M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $48.17M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $36.86M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $40.39M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $44.83M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $51.84M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $53.95M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $54.19M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $43.47M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $45.40M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $48.99M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $14.57M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $17.90M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $20.48M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $26.08M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $23.20M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $25.25M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $12.13M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $17.68M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $8.83M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $10.25M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $11.55M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $1.78M 10-K · filed 2021-03-11 | $12.97M 10-K · filed 2020-02-21 |
| 2019-09-30 | $14.98M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $17.68M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $19.43M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $16.04M 10-K · filed 2020-02-21 | |
| 2018-09-30 | $13.87M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $18.24M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $22.55M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $28.29M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $24.59M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $28.09M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $19.58M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $21.04M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $22.74M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $20.53M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $25.56M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $24.81M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $23.07M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $27.37M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $30.48M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $33.53M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $36.45M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $39.24M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $41.12M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $19.56M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $16.07M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $11.07M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $13.35M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $14.92M 10-K · filed 2014-03-21 | |
| 2012-09-30 | $7.98M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $9.76M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $11.71M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $13.69M 10-K · filed 2013-03-22 | |
| 2011-09-30 | $18.69M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $21.88M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $16.22M 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |